Geenen LW, et al. - Researchers investigated the release of soluble suppression of tumourigenicity-2 (sST2) and how it relates to cardiovascular events in adult congenital heart disease (ACHD) patients. In this prospective cohort study with 602 consecutive patients, the links between sST2 and a primary composite endpoint of all-cause mortality, heart failure, hospitalization, arrhythmia, thromboembolic events or cardiac interventions was investigated. When adjusted for age, sex, creatinine and N terminal pro-B type brain natriuretic peptide (NT-proBNP), sST2 was noted to be significantly correlated with the primary endpoint. When adjusted for clinical variables and NT-proBNP, this association was rendered null. A significant correlation between sST2 and the primary endpoint in stratified analysis in complex ACHD was observed when adjusted for clinical variables and NT-proBNP. They observed an association between sST2 and the primary endpoint in women, but not men, after the sex-specific analysis. These findings indicate that sST2 may be a capable and novel biomarker in patients with ACHD, particularly in complex ACHD and women.